Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer

The successes of targeted therapeutics against EGFR and ALK in non-small cell lung cancer (NSCLC) have demonstrated the substantial survival gains made possible by precision therapy. However, the majority of patients do not have tumors with genetic alterations responsive to these therapies, and ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Christopher T., Linger, Rachel M.A., Cohen, Rebecca A., Sather, Susan, Kirkpatrick, Gregory D., Davies, Kurtis D., DeRyckere, Deborah, Earp, H. Shelton, Graham, Douglas K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279384/
https://www.ncbi.nlm.nih.gov/pubmed/25372020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279384/
https://www.ncbi.nlm.nih.gov/pubmed/25372020

Ejemplares similares